![](/img/cover-not-exists.png)
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients
Giuseppe Visani, Massimo Breccia, Antonella Gozzini, Giorgina Specchia, Enrico Montefusco, Enrica Morra, Mario Annunziata, Andrea Camera, Francesco Cavazzini, Fabio Stagno, Patrizia Pregno, Emilio UsaVolume:
85
Year:
2010
Language:
english
Pages:
4
DOI:
10.1002/ajh.21871
File:
PDF, 640 KB
english, 2010